Search tips
Search criteria 


Logo of corrspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
Clin Orthop Relat Res. 2009 July; 467(7): 1921–1926.
Published online 2009 February 6. doi:  10.1007/s11999-009-0725-x
PMCID: PMC2690746

Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy

Arkan S. Sayed-Noor, MD, FEBOT, PhDcorresponding author1 and Göran O. Sjödén, MD, PhD1,2


Bisphosphonates are widely used for treatment of postmenopausal osteoporosis. Although short-term safety and efficacy of these drugs have been investigated and documented, an increasing number of recent reports draw attention to the possible correlation between long-term alendronate therapy and the occurrence of insufficiency fractures in the proximal femur owing to what is known as severely suppressed bone turnover. We describe two femoral insufficiency fractures in two women receiving long-term alendronate therapy. The first woman sustained a periprosthetic fracture at the tip of the femoral stem whereas the other woman had a fracture in the subtrochanteric region. We analyze the characteristics and natural course of these two unique fractures, and emphasize the importance of being aware of the possible correlation between long-term alendronate therapy and insufficiency femoral fractures.


Bisphosphonates are considered the first-line therapy of postmenopausal osteoporosis. They improve bone density and decrease fragility fractures mainly in the spine and hip [13, 6, 26]. They reduce bone resorption by inhibiting osteoclast function and promoting apoptosis [12, 18]. Alendronate was the first drug of this family to be approved by the US Food and Drug Administration in 1995. Since then, a large number of postmenopausal women and a smaller number of men with idiopathic, steroid-induced, or hypogonadal osteoporosis have been treated with alendronate.

The short-term efficacy and safety have been widely studied and documented [1, 2, 18, 26]. However, there have been concerns regarding possible adverse effects of long-term therapy. Although the drug is excreted extensively by the kidneys, the small amount that remains in the body may attach to the osteoid tissue for decades [9, 20]. Histomorphometric analysis of bone taken from patients receiving long-term alendronate shows changes consistent with severely suppressed bone turnover suggesting an adynamic bone disorder [19]. These changes include reduction in osteoid thickness and volume, reduced osteoblastic/osteoclastic surface, and diminished bone matrix. Consequently, this may give rise to failure of microfracture repair and secondary mineralization with increased brittleness and deterioration of the bone biomechanical properties. Currey [7] reported increasing bone mineralization gave high Young modulus of bone elasticity but low values of work of fracture (which is a measure of fracture toughness).

There have been an increasing number of reports regarding insufficiency femoral fractures in patients receiving long-term therapy with alendronate [2, 5, 11, 14, 15, 23, 24]. Clinical presentation of these fractures has been similar. The patient, typically a postmenopausal woman, sustains a fracture in the subtrochanteric region or the femoral shaft after low-energy trauma such as a gentle fall or twisting movement. Many of these patients experience prodromal pain in the affected limb several months before the occurrence of these insufficiency fractures. The radiographs show thickening of the cortex and transverse fracture line with medial spiking. Lateral cortical reaction is encountered on the contralateral side in some patients and is considered the first stage of these fractures. Delayed union or nonunion is common in these fractures. The etiology of the delayed union or nonunion in these patients is not clearly known but might be related to severely suppressed bone turnover.

In this report, we present two cases of femoral insufficiency fractures in two women receiving long-term alendronate therapy. In the first case, a woman sustained a periprosthetic femoral fracture, and in the second, another woman sustained a subtrochanteric femoral fracture.

Case Reports

Patient 1

A 78-year-old woman presented to the emergency room in March 2007 with pain of 1 week in the right thigh. The pain started after a same-level fall while walking. Six years previously, the patient had a Charnley prosthesis implanted for primary osteoarthritis of the right hip and she had no complaint thereafter until she fell. The patient was treated with 70 mg alendronate per week since 1998 for postmenopausal osteoporosis. No dual-energy xray absorptiometry measurement was obtained before starting alendronate therapy. The diagnosis of postmenopausal osteoporosis was made clinically when the patient sustained two distal radial fractures during 1998.

Her physical examination showed diffuse tenderness over the thigh muscles with normal range of motion (ROM) of the hip and knee. The radiographs revealed no signs of fracture or loosening such as a radiolucency at the bone-cement interface or changes in the stem position (Fig. 1). Complete blood picture (CBP) and C-reactive protein (CRP) were normal. Analgesics were prescribed for pain relief.

Fig. 1A B
(A) Anteroposterior and (B) lateral radiographs of Patient 1 were taken when the patient presented the first time with thigh pain on weightbearing. Cortical thickening and a 5-mm cortical focal bulge 10 mm distal to the stem tip (arrow) can be ...

In July 2007, the patient returned with increasing pain on weightbearing. New radiographs were taken, which showed thickening of the femoral shaft cortex with a fracture line below the tip of the femoral stem (Fig. 2). The new CBP, CRP, and serum calcium, phosphate, and vitamin D, were normal. No bone formation or resorption markers were investigated.

Fig. 2A B
(A) Anteroposterior and (B) lateral radiographs of Patient 1 were taken 4 months after her first visit. A transverse cortical fracture line now is seen through the previously noted focal bulge.

Reviewing radiographs from the time of her hip arthroplasty in 2001 revealed no cortical thickening of the femoral shaft at the time of surgery, whereas there was apparent cortical thickening with a lateral cortical reaction seen on the radiographs taken when the patient presented to us in March 2007 (Fig. 1).

At this time, a decision was made to treat the fracture nonoperatively with nonweightbearing. Clinical and radiographic followup after 6 months showed no improvement. Alendronate therapy then was stopped and the patient was scheduled for surgery. Preoperative radiographs showed a complete fracture going through both cortices (Fig. 3). The patient underwent open reduction and internal fixation with an angle-stable plating system with cable grip (Fig. 4). Postoperatively, the patient showed an improvement with minimal thigh pain on weightbearing with good ROM. At 5 months followup, radiographs showed callus formation bridging the fracture gap (Fig. 5), there was no tenderness over the fracture site, and the patient could bear weight without walking aids.

Fig. 3A B
(A) Anteroposterior and (B) lateral radiographs of Patient 1 were taken directly before surgery. The previously mentioned fracture is now slightly displaced.
Fig. 4A B
Postoperative (A) anteroposterior and (B) lateral radiographs of Patient 1 show the fracture fixed with an angle-stable plating system with cable grip.
Fig. 5A B
(A) Anteroposterior and (B) lateral radiographs of Patient 1 taken 5 months postoperatively show callus formation.

Patient 2

A 55-year-old woman with chronic alcoholic liver disease, hypertension, and a 10-year history of postmenopausal osteoporosis presented to the emergency room in January 2008 after falling on the floor at home. The patient’s osteoporosis had been diagnosed clinically (no dual-energy xray absorptiometry measurement was performed) when she sustained a vertebral compression fracture in 1999. Since that time, the patient was treated with vitamin D supplement and 70 mg alendronate weekly. At presentation, she had severe pain, swelling, and tenderness in the left thigh and her whole leg was shortened and externally rotated. Several months before the fall, she reported diffuse pain in both thighs with walking difficulties. Radiographs revealed a left-sided transverse subtrochanteric fracture (Type 32-A3.1 according to the AO classification) with cortical hypertrophy and medial spiking (Fig. 6). At the subtrochanteric region on the contralateral femur, a cortical hypertrophy with lateral cortical reaction was seen.

Fig. 6
An anteroposterior radiograph of Patient 2 shows the subtrochanteric fracture. Cortical thickening at the fracture site and a lateral cortical bulge at the subtrochanteric region of the contralateral femur suggest subtle early or stress fracture (arrow). ...

The next morning, the patient underwent insertion of a long gamma nail (Fig. 7) and received antibiotics and thrombosis prophylaxis. No tissue specimen was obtained during the operation because we could not identify any osteolytic lesions at the fracture site. There were no immediate postoperative complications and the patient was mobilized with the help of a walker. Followup of the patient 3 and 6 months postoperatively revealed gradual improvement with mild to moderate thigh pain on weightbearing. Her radiographs at those times showed increasing callus formation. Nine months postoperatively, the patient had minimal thigh pain and tenderness and the radiographs showed decreased fracture gap with bridging callus (Fig. 8). Our two patients were informed that data concerning their cases would be submitted for publication.

Fig. 7A B
(A) Anteroposterior and (B) lateral radiographs of Patient 2 show the subtrochanteric fracture after insertion of a long gamma nail. The transverse course of the fracture and medial spiking can be seen. The subcutaneous and fascial plane air is consistent ...
Fig. 8A B
(A) Anteroposterior and (B) lateral radiographs of Patient 2 taken 9 months postoperatively show the reduced fracture gap and bridging callus.


Insufficiency fractures of the femur have been reported either as secondary to metastatic osteolytic lesions or in relation to osteomalacia [4, 8], pycnodysostosis [13, 22], primary hyperparathyroidism [17], and in patients receiving fluoride therapy [25]. The occurrence of insufficiency femoral fractures in patients receiving long-term alendronate therapy was described by Neviaser et al. [18], Kwek et al. [14], and Goh et al. [11]. Neviaser et al. [18] identified insufficiency femoral fractures in 25 patients receiving long-term (average, 6.2 years) alendronate therapy. Nineteen of these patients exhibited a fracture pattern of a transverse fracture line, cortical hypertrophy, and medial spiking. Furthermore, Goh et al. [11] and Kwek et al. [14] reported 17 patients receiving long-term alendronate therapy (average, 4.8 years) with low-energy subtrochanteric fractures of a similar configuration. Nine patients had either a contralateral fracture or cortical reaction and 13 patients experienced thigh pain preceding the fracture occurrence.

Periprosthetic femoral fractures are uncommon, but the incidence seems to be increasing [16]. Gill et al. [10] reported two cases of lateral insufficiency periprosthetic femoral fractures caused by osteopenia and varus angulation of the stem with subsequent increased mechanical loading applied to the lateral cortex, which was extremely thinned on radiographs. They recommended revision of the stem and used noncemented Wagner implants with successful outcomes. In our Patient 1, the cortex was thickened and the stem was not angulated.

Localization of the fractures might be the result of the increased bending forces applied on the subtrochanteric area, as described by Pauwels [21], in our Patient 2 and below the tip of the implant in Patient 1. The delayed union in Patient 1 and involvement of the contralateral femur in Patient 2 were consistent with previously reported patients receiving long-term alendronate therapy and might indicate the pathology is not confined just to the site of the fractures. In Patient 2, we believe the fracture was related to severely suppressed bone turnover secondary to long-term alendronate therapy and not to the chronic liver disease because the patient’s overall liver function was well compensated despite chronicity and the typical presentation and characteristics of the fracture.

These two cases add another report emphasizing a possible relationship between long-term therapy with alendronate and severely suppressed bone turnover resulting in insufficiency fractures. In a patient receiving such therapy, groin or thigh pain should raise the suspicion of an insufficiency fracture and this type of fracture should be ruled out with repeated radiographs. Withdrawing alendronate therapy should be considered if investigations show early signs of such a fracture. We do not know if this possible adverse effect on bone is unique to alendronate or if it is shared with other bisphosphonates. Additional research is needed to study the long-term effect of this class of drugs on bone strength.


Each author certifies that he/she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.

Each author certifies that his or her institution has approved the reporting of these case reports, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.


1. Black D, Schwartz A, Ensrud K, Rybak-Feiglin A, Gupta J, Lombardi A, Wallace R, Levis S, Quandt S, Satterfield S, Cauley J, Cummings S. A 5 year randomized trial of the long-term efficacy and safety of alendronate. J Bone Mineral Res. 2004;10(suppl 1):S45.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. [PubMed]
3. Bone HG, Schurr W. Intravenous bisphosphonate therapy for osteoporosis: where do we stand? Curr Osteoporos Rep. 2004;2:24–30. [PubMed]
4. Chalmers J. Subtrochanteric fractures in osteomalacia. J Bone Joint Surg Br. 1970;52:509–513. [PubMed]
5. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007;13:485–489. [PubMed]
6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082. [PubMed]
7. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci. 1984;304:509–518. [PubMed]
8. Esterberg J, Kassim RA, Redmon J, Coad J, Macari GS, Saleh KJ. Hip pain in a case of hypophosphatemic osteomalacia. Am J Orthop. 2003;32:455–458. [PubMed]
9. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100. [PubMed]
10. Gill TJ, Sledge JB, Orler R, Ganz R. Lateral insufficiency fractures of the femur caused by osteopenia and varus angulation: a complication of total hip arthroplasty. J Arthroplasty. 1999;14:982–987. [PubMed]
11. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–353. [PubMed]
12. Kleerekoper M. Prevention of postmenopausal bone loss and treatment of osteoporosis. Semin Reprod Med. 2005;23:141–148. [PubMed]
13. Kundu ZS, Marya KM, Devgan A, Yadav V, Rohilla S. Subtrochanteric fracture managed by intramedullary nail in a patient with pycnodysostosis. Joint Bone Spine. 2004;71:154–156. [PubMed]
14. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–231. [PubMed]
15. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–1306. [PubMed]
16. Lindahl H. Epidemiology of periprosthetic femur fracture around total hip arthroplasty. Injury. 2007;38:651–654. [PubMed]
17. Morgan G, Ganapathi M, Afzal S, Grant AJ. Pathological fractures in primary hyperparathyroidism: a case report highlighting diagnostic difficulties. Injury. 2002;33:288–291. [PubMed]
18. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350. [PubMed]
19. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301. [PubMed]
20. Ott S. Long-term safety of bisphosphonates. Editorial. J Clin Endocrinol Metab. 2005;90:1897–1899. [PubMed]
21. Pauwels F. [The significance of the structural principles of the locomotor apparatus to resist the forces applied on long bones] [in German]. Anat Embryol. 1948;114:1–2.
22. Roth VG. Pycnodysostosis presenting with bilateral subtrochanteric fractures: case report. Clin Orthop Relat Res. 1976;117:247–253. [PubMed]
23. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop. 2008;79:565–567. [PubMed]
24. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006;61:31–33. [PubMed]
25. Schnitzler CM, Wing JR, Gear KA, Robson HJ. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res. 1990;261:268–275. [PubMed]
26. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85:3109–3115. [PubMed]

Articles from Clinical Orthopaedics and Related Research are provided here courtesy of The Association of Bone and Joint Surgeons